16 September, 2024
We are pleased to announce that we have successfully completed the FDA Establishment Registration & Device Listing, enhancing our commitment with the U.S. market. This milestone comes after receiving our FDA 510(k) clearance in 2021, which validated the safety and effectiveness of our MAPP® Solution.
To ensure compliance and ongoing communications with the FDA, we have appointed an U.S. Agent, qualifying us to leverage our solutions into the U.S. Market.
The Unidade Local de Saúde do Algarve initiated the use of mobility solutions, integrated into the MAPP® suite, for transfusion safety – BTrac® and medication administration – PharmaTrac®, in May, […]
+
